Considerable controversy exists regarding the safety of elective exogenous hormonal exposure among breast cancer survivors and women at high risk of developing the disease (referred to herein as 'previvors'). We performed a qualitative analysis focused on four areas of potential exogenous exposure to hormones among previvors and survivors: hormonal contraception; systemic hormone-replacement therapy (HRT); localized HRT; and hormonal manipulation for fertility preservation or enhancement. Herein, we discuss the available data and present clinical recommendations regarding the safety of hormonal exposure for both previvors and survivors. We found these data to be hampered by small cohort sizes, heterogeneous patient populations, and limited study designs, highlighting a great need to conduct further research with the aim of enabling better-informed patient management.

在乳腺癌幸存者和罹患该疾病的高风险女性（此处称为“幸存者”）中，选择性外源激素暴露的安全性存在相当大的争议。我们进行了定性分析，重点研究了幸存者和幸存者中激素可能外源性暴露的四个方面：激素避孕；激素避孕；激素预防；激素预防；激素治疗。全身激素替代疗法（HRT）；本地化的HRT; 和荷尔蒙操纵以保持或增强生育能力。在此，我们讨论了可用数据，并提出了关于激素对幸存者和幸存者的安全性的临床建议。我们发现这些数据受到较小的队列规模，异类患者人群和有限的研究设计的影响，